Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab vs rATG as Induction in de novo Renal Transplant Recipients
2023-507895-36-00Phase 2Completed
- Sponsor
- ITB-MED
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of siplizumab in kidney transplant (2 arms), sponsored by ITB-MED. Primary endpoints: Adverse events, Serious adverse events and 6 more. Started Feb 2024; status: completed.
02
Drugs
siplizumab
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2023-507895-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507895-36-00.